Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1 and pharmacologic open-label dose-escalation trial using a "3+3"
design. Successive cohorts of three or more patients will be treated at escalating doses
until a maximum tolerated dose is identified. Once the maximum tolerated dose is identified,
an Expansion Cohort will be enrolled at that dose to further characterize safety and
pharmacologic endpoints. Additional arms will be enrolled to explore the combination of
MM-302 with trastuzumab or trastuzumab plus cyclophosphamide in patients with advanced HER2
positive breast cancer.